{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:40Z","timestamp":1792025200326,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01841-z","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:16Z","timestamp":1792022836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Minoxidil and Prostaglandin Analogs for Chemotherapy-Induced Alopecia: A Scoping Review"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-8244","authenticated-orcid":false,"given":"Yohei","family":"Iimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"1841_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/SPC.0b013e3283409280","volume":"4","author":"RM Tr\u00fceb","year":"2010","unstructured":"Tr\u00fceb RM. Chemotherapy-induced alopecia. Curr Opin Support Palliat Care. 2010;4:281\u20134. https:\/\/doi.org\/10.1097\/SPC.0b013e3283409280.","journal-title":"Curr Opin Support Palliat Care"},{"key":"1841_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, et al. Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13:219\u201327. https:\/\/doi.org\/10.1007\/s00520-004-0710-6.","journal-title":"Support Care Cancer"},{"key":"1841_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1523-5394.2001.96007.x","volume":"9","author":"EL McGarvey","year":"2001","unstructured":"McGarvey EL, Baum LD, Pinkerton RC, Rogers LM. Psychological sequelae and alopecia among women with cancer. Cancer Pract. 2001;9:283\u20139.","journal-title":"Cancer Pract"},{"key":"1841_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF01262572","volume":"5","author":"K M\u00fcnstedt","year":"1997","unstructured":"M\u00fcnstedt K, Manthey N, Sachsse S, Vahrson H. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer. 1997;5:139\u201343.","journal-title":"Support Care Cancer"},{"key":"1841_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.abd.2020.03.005","volume":"95","author":"GB Silva","year":"2020","unstructured":"Silva GB, Ciccolini K, Donati A, Hurk CVD. Scalp cooling to prevent chemotherapy-induced alopecia. Bras Dermatol. 2020;95:631\u20137. https:\/\/doi.org\/10.1016\/j.abd.2020.03.005.","journal-title":"Bras Dermatol"},{"key":"1841_CR6","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.3390\/curroncol30040275","volume":"30","author":"TC Wikramanayake","year":"2023","unstructured":"Wikramanayake TC, Haberland NI, Akhundlu A, Laboy Nieves A, Miteva M. Prevention and treatment of chemotherapy-induced alopecia: What is available and what is coming? Curr Oncol. 2023;30:3609\u201326. https:\/\/doi.org\/10.3390\/curroncol30040275.","journal-title":"Curr Oncol"},{"key":"1841_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/oxfordjournals.annonc.a058986","volume":"5","author":"R Rodriguez","year":"1994","unstructured":"Rodriguez R, Machiavelli M, Leone B, Romero A, Cuevas MA, Langhi M, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin\u2014Induced alopecia. Ann Oncol. 1994;5:769\u201370. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058986.","journal-title":"Ann Oncol"},{"key":"1841_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-024-07440-5","volume":"208","author":"AMS Kuo","year":"2024","unstructured":"Kuo AMS, Reingold RE, Ketosugbo KF, Pan A, Kraehenbuehl L, Dusza S, et al. Oral minoxidil for late alopecia in cancer survivors. Breast Cancer Res Treat. 2024;208:491\u20139. https:\/\/doi.org\/10.1007\/s10549-024-07440-5.","journal-title":"Breast Cancer Res Treat"},{"key":"1841_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000548112","volume":"12","author":"CA Kearney","year":"2025","unstructured":"Kearney CA, Gordon A, Markova A, Freites-Martinez A, Tattersall IW, Shapiro J, et al. Low-dose oral minoxidil during chemotherapy: A review of the mechanism and current evidence. Skin Appendage Disord. 2025;12:29\u201337. https:\/\/doi.org\/10.1159\/000548112.","journal-title":"Skin Appendage Disord"},{"key":"1841_CR10","unstructured":"NCT05778825. A study of oral minoxidil to treat hair loss in children, teens, and young adults who are cancer survivors."},{"key":"1841_CR11","unstructured":"NCT05417308. Topical or oral minoxidil for the treatment of endocrine therapy-induced alopecia in patients with Stage I\u2013IV breast cancer."},{"key":"1841_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1524-6175.2004.03585.x","volume":"6","author":"DA Sica","year":"2004","unstructured":"Sica DA, Minoxidil. An underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich). 2004;6:283\u20137. https:\/\/doi.org\/10.1111\/j.1524-6175.2004.03585.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1841_CR13","doi-asserted-by":"publisher","unstructured":"Ibraheim MK, Elsensohn A, Hauschild C, Hilliard A, Dao H. Low dose oral minoxidil and the conundrum of cardiovascular complications. Dermatol Online J. 2023;29. https:\/\/doi.org\/10.5070\/D329461861.","DOI":"10.5070\/D329461861"},{"key":"1841_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/ijd.15378","volume":"60","author":"E Chovarda","year":"2021","unstructured":"Chovarda E, Sotiriou E, Lazaridou E, Vakirlis E, Ioannides D. The role of prostaglandins in androgenetic alopecia. Int J Dermatology. 2021;60:730\u20135. https:\/\/doi.org\/10.1111\/ijd.15378.","journal-title":"Int J Dermatology"},{"key":"1841_CR15","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/jidsymp.2013.30","volume":"16","author":"GS Ahluwalia","year":"2013","unstructured":"Ahluwalia GS. Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss. J Investig Dermatol Symp Proc. 2013;16:S73\u20136. https:\/\/doi.org\/10.1038\/jidsymp.2013.30.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1841_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","volume":"35","author":"M Duvic","year":"1996","unstructured":"Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35:74\u20138. https:\/\/doi.org\/10.1016\/S0190-9622(96)90500-9.","journal-title":"J Am Acad Dermatol"},{"key":"1841_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jaad.2022.12.005","volume":"88","author":"J Kang","year":"2023","unstructured":"Kang J, Lee JW, Kwon O. Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study. J Am Acad Dermatol. 2023;88:1170\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.005.","journal-title":"J Am Acad Dermatol"},{"key":"1841_CR18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jaad.2024.11.048","volume":"92","author":"D Zaminski","year":"2025","unstructured":"Zaminski D, Sikora M, Nohria A, Desai D, Buontempo M, Caplan AS, et al. Tolerability and effectiveness of low-dose oral minoxidil for alopecia in patients with breast cancer: A retrospective cohort study. J Am Acad Dermatol. 2025;92:906\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2024.11.048.","journal-title":"J Am Acad Dermatol"},{"key":"1841_CR19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jaad.2011.05.026","volume":"66","author":"U Blume-Peytavi","year":"2012","unstructured":"Blume-Peytavi U, L\u00f6nnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66:794\u2013800. https:\/\/doi.org\/10.1016\/j.jaad.2011.05.026.","journal-title":"J Am Acad Dermatol"},{"key":"1841_CR20","doi-asserted-by":"publisher","first-page":"e15450","DOI":"10.1111\/dth.15450","volume":"35","author":"M Rafati","year":"2022","unstructured":"Rafati M, Mahmoudian R, Golpour M, Kazeminejad A, Saeedi M, Nekoukar Z. The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial. Dermatol Ther. 2022;35:e15450. https:\/\/doi.org\/10.1111\/dth.15450.","journal-title":"Dermatol Ther"},{"key":"1841_CR21","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","volume":"14","author":"R Paus","year":"2013","unstructured":"Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14:e50\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(12)70553-3.","journal-title":"Lancet Oncol"},{"key":"1841_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1634\/theoncologist.2017-0263","volume":"23","author":"CJ Dunnill","year":"2018","unstructured":"Dunnill CJ, Al-Tameemi W, Collett A, Haslam IS, Georgopoulos NT. A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention. Oncologist. 2018;23:84\u201396. https:\/\/doi.org\/10.1634\/theoncologist.2017-0263.","journal-title":"Oncologist"},{"key":"1841_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2133.2004.05785.x","volume":"150","author":"AG Messenger","year":"2004","unstructured":"Messenger AG, Rundegren J, Minoxidil. Mechanisms of action on hair growth. Br J Dermatol. 2004;150:186\u201394. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.05785.x.","journal-title":"Br J Dermatol"},{"key":"1841_CR24","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1096\/fj.07-099424","volume":"22","author":"K Shorter","year":"2008","unstructured":"Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008;22:1725\u201336. https:\/\/doi.org\/10.1096\/fj.07-099424.","journal-title":"FASEB J"},{"key":"1841_CR25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1346-8138.1990.tb01641.x","volume":"17","author":"O Mori","year":"1990","unstructured":"Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol. 1990;17:276\u201381. https:\/\/doi.org\/10.1111\/j.1346-8138.1990.tb01641.x.","journal-title":"J Dermatol"},{"key":"1841_CR26","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.abd.2023.08.016","volume":"99","author":"BD Sanabria","year":"2024","unstructured":"Sanabria BD, Perdomo YC, Miot HA, Ramos PM. Oral minoxidil 7.5\u00a0mg for hair loss increases heart rate with no change in blood pressure in 24\u00a0h Holter and 24\u00a0h ambulatory blood pressure monitoring. Bras Dermatol. 2024;99:734\u20136. https:\/\/doi.org\/10.1016\/j.abd.2023.08.016.","journal-title":"Bras Dermatol"},{"key":"1841_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jdermsci.2023.02.005","volume":"109","author":"SF Lai","year":"2023","unstructured":"Lai SF, Huang WY, Wang WH, Hong JB, Kuo SH, Lin SJ. Prostaglandin E2 prevents radiotherapy-induced alopecia by attenuating transit amplifying cell apoptosis through promoting G1 arrest. J Dermatol Sci. 2023;109:117\u201326. https:\/\/doi.org\/10.1016\/j.jdermsci.2023.02.005.","journal-title":"J Dermatol Sci"},{"key":"1841_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0360-3016(92)90750-C","volume":"23","author":"WR Hanson","year":"1992","unstructured":"Hanson WR, Pelka AE, Nelson AK, Malkinson FD. Subcutaneous or topical administration of 16,16 dimethyl prostaglandin E2 protects from radiation-induced alopecia in mice. Int J Radiat Oncol Biol Phys. 1992;23:333\u20137. https:\/\/doi.org\/10.1016\/0360-3016(92)90750-C.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1841_CR29","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1111\/1523-1747.ep12363200","volume":"101","author":"FD Malkinson","year":"1993","unstructured":"Malkinson FD, Geng L, Hanson WR. Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin. J Invest Dermatol. 1993;101:S135\u20137. https:\/\/doi.org\/10.1111\/1523-1747.ep12363200.","journal-title":"J Invest Dermatol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01841-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01841-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01841-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:17Z","timestamp":1792022837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01841-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01841-z","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YI received lecture fees from Taiho Pharmaceutical Co., Ltd, and Chugai Pharmaceutical Co., Ltd. SK, TY, and HH have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"103"}}